3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
9
Carcinoma, Transitional Cell
7
Carcinoma, Merkel Cell
6
Neoplasm Metastasis
5
Breast Neoplasms
5
Carcinoma, Renal Cell
4
Urethral Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Skin Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neuroendocrine Tumors
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Penile Squamous Cell Carcinoma (PSCC)
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Interventions
Specimen Handling
4
Gemcitabine
4
Fluorouracil
4
Bevacizumab
4
fludarabine
3
aldesleukin
3
Radiosurgery
3
Oxaliplatin
3
Endoscopic Mucosal Resection
3
Cyclophosphamide
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
Tomography, X-Ray Computed
2
Surveys and Questionnaires
2
Sunitinib
2
Pemetrexed
2
Leucovorin
2
IDRX-42
2
Folfox protocol
2
Endoscopy, Digestive System
2
Biopsy
2
trastuzumab deruxtecan
1
tislelizumab
1
sodium thiosulfate
1
sodium propionate
1
semaglutide
1
s-formylglutathione hydrolase
1
repotrectinib
1
regorafenib
1
plecanatide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
avelumab
×
90 days
×
Clear all
No trials found.